The maturity dates of the Notes are expected to range from two to 40 years. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by
This offering is being made pursuant to an effective shelf registration statement and prospectus and a related preliminary prospectus supplement filed by the Issuer and
Copies of the prospectus supplement and related prospectus for this offering can be obtained from
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, including the Notes. There shall not be any sale of the securities described herein in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About
At
Forward-Looking Statements
This press release may include forward-looking statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve substantial risks and uncertainties and potentially inaccurate assumptions. We have tried, wherever possible, to identify such statements by using words such as 'will,' 'may,' 'could,' 'likely,' 'ongoing,' 'anticipate,' 'estimate,' 'expect,' 'project,' 'intend,' 'plan,' 'believe,' 'assume,' 'target,' 'forecast,' 'guidance,' 'goal,' 'objective,' 'aim,' 'seek,' 'potential,' 'hope' and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, the intended use of proceeds of the offering, our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data that become available, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics and size, growth, performance, timing of exclusivity and potential benefits; strategic reviews, capital allocation objectives, dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on growth opportunities and prospects; sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings; expectations for impact of or changes to existing or new government regulations or laws; our ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises and manufacturing and product supply.
In particular, forward-looking information in this press release includes statements relating to the expected terms of the Notes offering and the use of proceeds to finance a portion of the Merger consideration.
A list and description of risks, uncertainties and other matters can be found in
We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, and you are cautioned not to put undue reliance on forward-looking statements.
We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the
Contact:
Tel: +1 (212) 733-1226
Email: PfizerMediaRelations@pfizer.com
(C) 2023 Electronic News Publishing, source